CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
In July, we reported that lecanemab (Leqembi) won full FDA approval to treat Alzheimer's disease. In this article, we look beyond anti-amyloid agents like lecanemab to see what other targets are being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback